These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1077 related items for PubMed ID: 22082647

  • 1. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
    Martínez-Navarro EM, Rebollo J, González-Manzano R, Sureda M, Evgenyeva E, Valenzuela B, Fernández FJ, Forteza J, Brugarolas A.
    Clin Transl Oncol; 2011 Nov; 13(11):812-8. PubMed ID: 22082647
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T, Mori M, Yano Y, Uchida J, Nishino K, Kaji R, Hata A, Hattori Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S, Morita S, Yokota S.
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [Abstract] [Full Text] [Related]

  • 3. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
    Gazdar AF.
    Oncogene; 2009 Aug; 28 Suppl 1(Suppl 1):S24-31. PubMed ID: 19680293
    [Abstract] [Full Text] [Related]

  • 4. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC, Lim CK, Chang LY, Chen KY, Shih JY, Yu CJ.
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
    Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB.
    Sci Transl Med; 2013 Dec 18; 5(216):216ra177. PubMed ID: 24353160
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.
    Lin CC, Yang JC.
    Drugs; 2011 Jan 01; 71(1):79-88. PubMed ID: 21175241
    [Abstract] [Full Text] [Related]

  • 9. Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.
    Ying H, Yang XD, Sun Z, Ning X, Wang Y, Bai C, Chen S, Wang Y.
    Med Oncol; 2014 Oct 01; 31(10):220. PubMed ID: 25216867
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.
    Yang CH.
    Lung Cancer; 2008 Jun 01; 60 Suppl 2():S23-30. PubMed ID: 18513581
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
    Sun JM, Won YW, Kim ST, Kim JH, Choi YL, Lee J, Park YH, Ahn JS, Park K, Ahn MJ.
    J Cancer Res Clin Oncol; 2011 Apr 01; 137(4):687-94. PubMed ID: 20552223
    [Abstract] [Full Text] [Related]

  • 17. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J, Qu L, Wei X, Gao H, Wang W, Qin H, Tang C, Guo W, Wang H, Liu X.
    Zhongguo Fei Ai Za Zhi; 2012 May 01; 15(5):299-304. PubMed ID: 22613337
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.
    Cochrane Database Syst Rev; 2016 May 25; (5):CD010383. PubMed ID: 27223332
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.